Connexin43, A Promising Target to Reduce Cardiac Arrhythmia Burden in Pulmonary Arterial Hypertension

Matus Sykora,Barbara Szeiffova Bacova,Katarina Andelova,Tamara Egan Benova,Adriana Martiskova,Lin-Hai Kurahara,Katsuya Hirano,Narcis Tribulova
DOI: https://doi.org/10.3390/ijms25063275
IF: 5.6
2024-03-14
International Journal of Molecular Sciences
Abstract:While essential hypertension (HTN) is very prevalent, pulmonary arterial hypertension (PAH) is very rare in the general population. However, due to progressive heart failure, prognoses and survival rates are much worse in PAH. Patients with PAH are at a higher risk of developing supraventricular arrhythmias and malignant ventricular arrhythmias. The latter underlie sudden cardiac death regardless of the mechanical cardiac dysfunction. Systemic chronic inflammation and oxidative stress are causal factors that increase the risk of the occurrence of cardiac arrhythmias in hypertension. These stressful factors contribute to endothelial dysfunction and arterial pressure overload, resulting in the development of cardiac pro-arrhythmic conditions, including myocardial structural, ion channel and connexin43 (Cx43) channel remodeling and their dysfunction. Myocardial fibrosis appears to be a crucial proarrhythmic substrate linked with myocardial electrical instability due to the downregulation and abnormal topology of electrical coupling protein Cx43. Furthermore, these conditions promote ventricular mechanical dysfunction and heart failure. The treatment algorithm in HTN is superior to PAH, likely due to the paucity of comprehensive pathomechanisms and causal factors for a multitargeted approach in PAH. The intention of this review is to provide information regarding the role of Cx43 in the development of cardiac arrhythmias in hypertensive heart disease. Furthermore, information on the progress of therapy in terms of its cardioprotective and potentially antiarrhythmic effects is included. Specifically, the benefits of sodium glucose co-transporter inhibitors (SGLT2i), as well as sotatercept, pirfenidone, ranolazine, nintedanib, mirabegron and melatonin are discussed. Discovering novel therapeutic and antiarrhythmic strategies may be challenging for further research. Undoubtedly, such research should include protection of the heart from inflammation and oxidative stress, as these are primary pro-arrhythmic factors that jeopardize cardiac Cx43 homeostasis, the integrity of intercalated disk and extracellular matrix, and, thereby, heart function.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
The paper aims to explore the impact of connexin43 (Cx43) on cardiac arrhythmias in pulmonary arterial hypertension (PAH) and proposes the potential of Cx43 as a therapeutic target. Specifically, the paper focuses on the following aspects: 1. **Background and Issues**: - Pulmonary arterial hypertension (PAH) is a rare but rapidly progressing and potentially life-threatening disease characterized by elevated pulmonary artery pressure. - Patients are prone to atrial fibrillation (AF) and malignant ventricular arrhythmias, which are among the main causes of sudden death. 2. **Mechanism of Action of Cx43**: - In a normal heart, Cx43 is primarily distributed at the intercalated discs between cardiomyocytes, responsible for electrical conduction. - In PAH patients, the expression of Cx43 is reduced and abnormally distributed, shifting from the normal intercalated disc location to the lateral sides of cardiomyocytes, leading to electrical conduction disturbances. - These changes promote the occurrence of reentrant arrhythmias, increasing the risk of arrhythmias. 3. **Impact of Inflammation and Oxidative Stress**: - Systemic inflammation and oxidative stress are important triggers of PAH, leading to myocardial remodeling and Cx43 dysfunction. - These factors collectively act on cardiomyocytes, making them more susceptible to arrhythmias. 4. **Therapeutic Strategies**: - The paper discusses various potential therapeutic approaches, such as sodium-glucose cotransporter inhibitors (SGLT2i), sotatercept, pirfenidone, ranolazine, nintedanib, mirabegron, and melatonin. - These drugs protect cardiac function by alleviating inflammation, oxidative stress, and myocardial remodeling. In summary, the paper aims to reveal the critical role of Cx43 in cardiac arrhythmias in PAH and explores new methods to prevent or treat arrhythmias by regulating Cx43.